Atyr Pharma Inc. (LIFE) Stock Rating Upgraded by Zacks Investment Research
Atyr Pharma Inc. (NASDAQ:LIFE) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday. The brokerage presently has a $4.00 target price on the stock. Zacks Investment Research’s price objective indicates a potential upside of 6.67% from the stock’s current price.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
A number of other research analysts have also weighed in on LIFE. BMO Capital Markets set a $8.00 target price on shares of Atyr Pharma and gave the company a “hold” rating in a report on Thursday, October 6th. Citigroup Inc. raised their target price on shares of Atyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Tuesday, August 16th. Finally, JPMorgan Chase & Co. cut their target price on shares of Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, August 11th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $6.50.
Shares of Atyr Pharma (NASDAQ:LIFE) opened at 3.75 on Thursday. The company’s 50-day moving average is $2.98 and its 200-day moving average is $3.06. The company’s market capitalization is $88.94 million. Atyr Pharma has a 12-month low of $2.48 and a 12-month high of $10.93.
Atyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings data on Monday, November 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.09. Analysts predict that Atyr Pharma will post ($2.54) EPS for the current year.
A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Atyr Pharma by 120.3% in the second quarter. Vanguard Group Inc. now owns 439,732 shares of the company’s stock worth $1,223,000 after buying an additional 240,101 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in shares of Atyr Pharma by 317.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 344,214 shares of the company’s stock worth $957,000 after buying an additional 261,753 shares in the last quarter. BlackRock Advisors LLC increased its stake in shares of Atyr Pharma by 14,820.9% in the second quarter. BlackRock Advisors LLC now owns 244,405 shares of the company’s stock worth $679,000 after buying an additional 242,767 shares in the last quarter. Emerald Acquisition Ltd. increased its stake in shares of Atyr Pharma by 43.2% in the third quarter. Emerald Acquisition Ltd. now owns 106,410 shares of the company’s stock worth $339,000 after buying an additional 32,100 shares in the last quarter. Finally, Jackson Park Capital LLC bought a new stake in shares of Atyr Pharma during the second quarter worth about $183,000. Institutional investors own 44.63% of the company’s stock.
About Atyr Pharma
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Stock Ratings for Atyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr Pharma Inc. and related stocks with our FREE daily email newsletter.